Community Acquired Pneumonia (CAP)
Summary
Community Acquired Pneumonia (CAP) is an acute infection of the lung parenchyma acquired outside of a hospital setting. It is a major cause of mortality, especially in the elderly. The commonest pathogen is Streptococcus pneumoniae (Pneumococcus). Severity is risk-stratified using the CURB-65 score. [1,2]
Clinical Pearls
The "Atypical" Screen: Atypicals (Legionella, Mycoplasma, Chlamydia) don't have cell walls, so Penicillins (Amoxicillin) DO NOT WORK. You must add a Macrolide (Clarithromycin) or Tetracycline (Doxycycline) if you suspect them. Suspect atypicals if: Young patient, dry cough, extra-pulmonary symptoms (rash, hepatitis, hyponatraemia), or failure to respond to Amoxicillin.
Legionella: Think of this in patients who have recently travelled (hotel air conditioning) or handle soil. Classic triad: Pneumonia + Hyponatraemia + Deranged LFTs.
Klebsiella: The "Red Currant Jelly Sputum" pneumonia. Classic in Alcoholics and Diabetics. Upper lobe cavitating pneumonia (looks like TB).
Incidence and Mortality
- Global Burden: 450 million cases annually. 4 million deaths (WHO). Leading infectious cause of death worldwide.
- UK Incidence: 5-11 per 1000 adults per year. Higher in winter months (November-March).
- Age Distribution: Bimodal - children less than 5 years and adults >65 years.
- Mortality:
- Community (outpatients): less than 1% (CURB 0-1).
- Hospital (inpatients): 5-10% (CURB 2).
- ICU (severe): 15-40% (CURB 3-5).
- Overall: 5-12% of hospitalized patients.
Causative Organisms
Typical Bacteria (Cell Wall Present - Respond to Penicillins)
1. Streptococcus pneumoniae (Pneumococcus) - 30-50% of Cases
- Most common cause of CAP in all age groups.
- Gram-positive diplococci (pairs). Lancet-shaped.
- Transmission: Respiratory droplets, colonizes nasopharynx.
- Risk Factors: Elderly, smoking, COPD, asplenia (encapsulated organism), immunosuppression, alcoholism.
- Clinical Features: Abrupt onset, high fever, rusty sputum (blood-tinged), lobar consolidation on CXR.
- Complications: Bacteremia (25%), meningitis, empyema.
- Prevention: Pneumococcal vaccine (PPV23 polysaccharide or PCV13 conjugate) for elderly, asplenic, immunocompromised.
2. Haemophilus influenzae - 5-20%
- Gram-negative coccobacillus.
- Risk Factors: COPD (most important), smoking, bronchiectasis, elderly.
- Clinical Features: Often exacerbation of COPD with pneumonia. Patchy bronchopneumonia.
- Note: Vaccine (Hib) protects against invasive disease (meningitis) but not respiratory disease.
3. Moraxella catarrhalis - 1-2%
- Gram-negative diplococci.
- Risk Factors: COPD, elderly, immunocompromised.
- Clinical Features: Mild pneumonia, often coexists with H. influenzae in COPD exacerbations.
4. Staphylococcus aureus - 5% (Higher in Pandemics)
- Gram-positive cocci in clusters.
- Classic Scenario: Post-influenza pneumonia (2-14 days after flu). Secondary bacterial infection.
- Risk Factors: Recent flu (Influenza A/B), IV drug use (endocarditis → septic emboli), aspiration (nursing home residents).
- Clinical Features: Necrotizing pneumonia, cavitation, bilateral patchy infiltrates. Rapidly progressive. High mortality (30-40%).
- MRSA: Community-acquired MRSA (CA-MRSA) produces Panton-Valentine Leukocidin (PVL) toxin → necrotizing pneumonia, hemoptysis. Often young, healthy adults. Treat with Linezolid or Vancomycin.
5. Klebsiella pneumoniae - less than 5%
- Gram-negative rod. Encapsulated (mucoid colonies).
- Risk Factors: Alcoholics (most important), diabetes, nursing home residents, aspiration.
- Clinical Features: Upper lobe cavitating pneumonia (mimics TB). "Red currant jelly" sputum (blood-stained, thick). Bulging fissure sign (expansion of consolidation). High mortality (30-50%).
Atypical Bacteria (No Cell Wall - Penicillins DO NOT WORK)
1. Mycoplasma pneumoniae - 10-20% (Epidemics Every 4 Years)
- Smallest free-living organism. No cell wall.
- Transmission: Respiratory droplets. Incubation 2-3 weeks. "Walking pneumonia" (patients not very unwell, continue daily activities).
- Demographics: Young adults (15-40 years), college students, military recruits.
- Clinical Features:
- Dry cough (non-productive initially).
- Extra-pulmonary manifestations (20-30%):
- Skin: Erythema multiforme, Stevens-Johnson syndrome.
- Hematological: Cold agglutinins (IgM autoantibodies → hemolytic anemia). Positive in 50%.
- Neurological: Meningoencephalitis, Guillain-Barré syndrome, transverse myelitis.
- Cardiac: Myocarditis, pericarditis.
- CXR worse than clinical picture (extensive infiltrates but patient not very breathless).
- Diagnosis: Cold agglutinins (bedside clumping test), Mycoplasma IgM serology, PCR.
- Treatment: Macrolides (Clarithromycin, Azithromycin) or Tetracyclines (Doxycycline).
2. Legionella pneumophila - 2-15% (Higher in Hospital Outbreaks)
- Gram-negative rod. Intracellular organism. Lives in water systems (hot tubs, air conditioning, showers).
- Transmission: Inhalation of aerosolized water droplets (not person-to-person).
- Risk Factors: Travel (hotels, cruise ships), soil exposure, smoking, COPD, immunosuppression.
- Clinical Features:
- Classic Triad: Pneumonia + Hyponatremia (SIADH) + Deranged LFTs.
- Relative bradycardia: Pulse-temperature dissociation (fever without proportional tachycardia).
- GI symptoms: Diarrhea (50%), abdominal pain, vomiting.
- CNS: Confusion, headache.
- CXR: Often bibasal, rapidly progressive.
- Diagnosis: Urinary antigen (rapid, only detects serogroup 1 - 80% of cases). Sputum culture on BCYE agar (takes 3-5 days).
- Treatment: Fluoroquinolones (Levofloxacin) or Macrolides (Azithromycin). Do not use Penicillins.
3. Chlamydophila pneumoniae - 5-10%
- Obligate intracellular bacterium. No peptidoglycan wall.
- Transmission: Respiratory droplets.
- Clinical Features: Mild, dry cough, pharyngitis (sore throat), hoarseness. Often misdiagnosed as viral URTI.
- CXR: Interstitial infiltrates.
- Diagnosis: Serology (IgM, IgG), PCR.
- Treatment: Macrolides or Tetracyclines.
Viral Causes - 10-20% (Higher in Pandemics)
1. Influenza A/B
- Most common viral cause of severe CAP.
- Presentation: Abrupt onset, high fever, myalgia, headache. Primary viral pneumonia OR secondary bacterial (Staph, Pneumococcus).
- CXR: Bilateral infiltrates.
- Diagnosis: Rapid antigen test (nasopharyngeal swab), PCR.
- Treatment: Oseltamivir (Tamiflu) if less than 48h from symptom onset. Antibiotics for secondary bacterial pneumonia.
2. SARS-CoV-2 (COVID-19)
- Pandemic 2020-present. Now endemic.
- Presentation: Cough, fever, breathlessness, loss of smell/taste. Bilateral ground-glass opacities on CT. ARDS in severe cases.
- Treatment: Oxygen, Dexamethasone (if hypoxic), Remdesivir (in some settings). Antibiotics only if bacterial superinfection suspected.
3. Respiratory Syncytial Virus (RSV)
- Common in infants and elderly. Bronchiolitis in infants, CAP in elderly/immunocompromised.
4. Adenovirus, Parainfluenza, Human Metapneumovirus (hMPV)
- Less common. Usually mild, self-limiting.
Risk Factors for CAP
Non-Modifiable
- Age: >65 years (immune senescence, impaired cough reflex, comorbidities).
- Male Sex: 1.5x higher risk than females.
Modifiable
- Smoking: 2-4x increased risk. Impairs mucociliary clearance, damages epithelium, alters immune response.
- Alcohol Excess: Impairs cough reflex, aspiration risk, suppresses immunity, Klebsiella risk.
- Malnutrition: BMI less than 18.5. Impairs immunity.
- Poor Dentition: Aspiration of oral flora.
Comorbidities
- COPD (most important chronic disease risk factor): 5-10x risk. H. influenzae, Moraxella common.
- Asthma: 2x risk (especially if poorly controlled, oral steroids).
- Heart Failure: Pulmonary edema increases infection susceptibility.
- Diabetes Mellitus: Hyperglycemia impairs neutrophil function. 3x risk.
- CKD: Uremia impairs immunity.
- Immunosuppression: HIV, steroids (>20mg prednisolone daily), chemotherapy, biologics (anti-TNF, Rituximab).
- Asplenia / Hyposplenia: ↑risk of encapsulated organisms (Pneumococcus, H. influenzae, Meningococcus). Give vaccines.
Social
- Overcrowding: Care homes, prisons, military barracks, homeless shelters.
- Seasonal: Winter months (flu season, close indoor contact).
5-Step Mechanism of Pneumonia Development
1. Microbial Entry into Lower Respiratory Tract
Routes:
- Microaspiration: Most common. Silent aspiration of oropharyngeal secretions during sleep (occurs in 45% of healthy people). If bacterial load high or immune system weak → pneumonia.
- Inhalation: Aerosol droplets from coughing/sneezing (Mycoplasma, Legionella, Influenza).
- Hematogenous Spread: Bacteremia seeds lungs (Staph aureus from endocarditis → septic emboli).
- Direct Extension: From adjacent infection (empyema, subphrenic abscess).
Normal Defenses (Protect Against Infection):
- Upper airway: Nasal hairs, mucus, nasopharynx filters particles >10 microns.
- Tracheobronchial tree: Mucociliary escalator (cilia beat mucus upward, trapping bacteria). Cough reflex.
- Alveolar: Alveolar macrophages (phagocytose bacteria). Surfactant (opsonizes bacteria). Immunoglobulins (IgA, IgG).
Failure of Defenses:
- Impaired cough: Elderly, neurological disease (stroke, dementia), anesthesia, sedation.
- Impaired mucociliary clearance: Smoking (paralyzes cilia), viral infection (flu damages epithelium), COPD.
- Immunosuppression: HIV, steroids, chemotherapy, asplenia.
- High bacterial load: Aspiration of large volume (alcoholic blackout, seizure).
2. Bacterial Adherence and Colonization
- Bacteria adhere to respiratory epithelium using adhesins (pili, fimbriae, surface proteins).
- S. pneumoniae: Pneumolysin toxin damages epithelium, allowing invasion.
- H. influenzae: IgA protease degrades mucosal IgA.
- Colonization of normally sterile lower airways and alveoli.
3. Innate Immune Response (Inflammation)
- Pathogen Recognition: Alveolar macrophages recognize bacteria via Pattern Recognition Receptors (PRRs - Toll-like receptors).
- Cytokine Release: Macrophages release pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8).
- Neutrophil Recruitment: Cytokines attract neutrophils (polymorphonuclear leukocytes - PMNs) from bloodstream to alveoli.
- Capillary Leak: Inflammation increases vascular permeability → fluid, protein, and cells leak into alveoli.
4. Alveolar Consolidation (Pathological Hallmark)
- Alveoli fill with inflammatory exudate:
- Neutrophils (pus cells).
- Bacteria.
- Fibrin.
- Red blood cells (if hemorrhagic).
- Fluid (edema).
- Gas Exchange Impaired:
- Consolidated alveoli cannot participate in gas exchange.
- V/Q Mismatch: Perfusion (Q) continues but Ventilation (V) is zero → shunt → Type 1 Respiratory Failure (hypoxemia, normal/low CO₂).
- Hypoxia → compensatory hyperventilation → tachypnea.
Classical Stages of Lobar Pneumonia (Pneumococcal):
- Congestion (Day 1-2): Vascular engorgement, bacterial proliferation. Lung heavy, red.
- Red Hepatization (Day 3-4): Alveoli full of RBCs, neutrophils, fibrin. Lung resembles liver (firm, airless).
- Gray Hepatization (Day 5-7): RBCs breakdown, leaving neutrophils and fibrin. Lung gray, firm.
- Resolution (Day 8-14): Enzymatic digestion of exudate. Macrophages clear debris. Type II pneumocytes regenerate (lung architecture preserved).
Bronchopneumonia (Patchy):
- Multiple foci of consolidation (lobular, not lobar).
- Common with Staph, H. influenzae, Gram-negatives, aspiration.
- Less organized, more necrotizing.
5. Resolution OR Complications
Normal Resolution (70-80% of Cases):
- Effective antibiotic therapy + intact immune system → bacterial clearance.
- Inflammatory exudate resorbed/expectorated.
- Type II pneumocytes regenerate alveolar epithelium.
- Lung architecture preserved (no scarring if treated early).
- CXR clears over 4-12 weeks (lags behind clinical recovery).
Complications (If Untreated or Severe):
- Parapneumonic Effusion / Empyema (see Complications section).
- Lung Abscess: Necrotizing pneumonia → cavity with pus.
- Sepsis / Septic Shock: Bacteremia → systemic inflammatory response.
- Respiratory Failure: ARDS (acute respiratory distress syndrome).
- Metastatic Infection: Meningitis (Pneumococcus), endocarditis (Staph).
Pathogen-Specific Pathophysiology
Streptococcus pneumoniae:
- Pneumolysin toxin: Pore-forming toxin → kills host cells, activates complement, triggers inflammation.
- Polysaccharide capsule: Prevents phagocytosis (hence vaccine targets capsule).
- Classic lobar consolidation.
Staphylococcus aureus:
- Toxins (PVL, alpha-toxin): Destroy neutrophils, cause tissue necrosis.
- Necrotizing pneumonia: Rapid cavitation, abscesses, hemorrhage.
- MRSA: Resistance to beta-lactams (mecA gene).
Legionella:
- Intracellular pathogen: Survives inside alveolar macrophages (evades killing).
- Replicates in phagosomes.
- Multi-organ dysfunction: SIADH (hyponatremia), hepatitis (↑LFTs), myocarditis, encephalitis.
Mycoplasma:
- Lacks cell wall → immune response directed at host tissues (autoimmunity).
- Cold agglutinins: IgM antibodies against RBCs → hemolytic anemia.
- Extra-pulmonary manifestations common (erythema multiforme, meningoencephalitis).
| Condition | Distinguishing Feature |
|---|---|
| Pneumonia | Productive cough. Bronchial breathing. Fever. |
| PE | Pleuritic pain. Tachycardia. Clear chest or wedge infarct. |
| Heart Failure | Bilateral basal crackles. JVP high. Orthopnoea. |
| Acute Asthma/COPD | Wheeze. History. |
| Malignancy | Chronic. Cachexia. |
Symptoms
Classical Presentation (Typical Bacterial Pneumonia - Pneumococcus)
Atypical Presentation
Mycoplasma ("Walking Pneumonia"):
Legionella:
Viral (Influenza, COVID-19):
Aspiration Pneumonia:
Atypical Presentations in Special Groups
Elderly:
Immunocompromised (HIV, Chemotherapy):
Signs (Physical Examination)
General
Respiratory
Inspection:
Palpation:
Percussion:
Auscultation:
Classical Signs of Lobar Consolidation:
Cardiovascular / Sepsis
Severity Assessment: CURB-65 Score
Purpose: Risk stratification to guide admission decision and antibiotic choice.
Score 1 point for each criterion:
| Letter | Criterion | Definition |
|---|---|---|
| C | Confusion | New onset disorientation (person, place, time). AMTS ≤8/10 (Abbreviated Mental Test Score). |
| U | Urea | Blood urea >7 mmol/L. Marker of renal hypoperfusion (sepsis, dehydration). |
| R | Respiratory Rate | RR ≥30 breaths/min. Compensatory tachypnea (hypoxia). |
| B | Blood Pressure | Systolic BP less than 90 mmHg OR Diastolic BP ≤60 mmHg. Septic shock marker. |
| 65 | Age | ≥65 years. |
Risk Stratification and Management:
| Score | Risk | Mortality | Management | Setting |
|---|---|---|---|---|
| 0-1 | Low | less than 3% | Oral antibiotics. Consider home treatment. Safety net advice. | Outpatient (home or ambulatory care). |
| 2 | Intermediate | 9% | Admission. IV or oral antibiotics. Consider short stay unit. | Hospital ward |
| 3-5 | High | 15-40% | Urgent admission. IV antibiotics immediately. Fluid resuscitation. Consider ICU/HDU. Consultant review. | ICU/HDU consideration |
CRB-65 (Community Version):
- Omits Urea (not available in community).
- Score 0: Outpatient. Score 1-2: Consider admission. Score ≥3: Urgent admission.
Limitations of CURB-65:
- Age bias: Automatically scores ≥2 if ≥65 years (even if otherwise well). May over-admit elderly.
- Doesn't capture all severity: Doesn't include oxygen saturation, comorbidities, social factors.
- Use clinical judgment: CURB-65 is a guide, not absolute. Consider: hypoxia (SpO₂ less than 92%), multilobar involvement, inability to take oral meds, social circumstances (lives alone, frail).
Imaging
Chest X-Ray (CXR) - Essential First-Line
Timing: Should be done in all patients with suspected pneumonia (to confirm diagnosis and assess extent).
Classical Patterns:
| Pattern | Description | Likely Organism | Image Features |
|---|---|---|---|
| Lobar Pneumonia | Homogeneous consolidation confined to one lobe. | S. pneumoniae (most common). | Air bronchograms (air-filled bronchi visible against consolidated alveoli - pathognomonic). Well-defined borders at fissures. |
| Bronchopneumonia | Patchy, multifocal consolidation. Bilateral, scattered. | Staph aureus, H. influenzae, Gram-negatives, Aspiration. | Ill-defined borders. Multiple foci. Peri-hilar distribution. |
| Interstitial Pneumonia | Reticular or ground-glass opacities. Preserved lung volumes. | Atypicals (Mycoplasma, Viruses, Pneumocystis). | Fine linear markings. Ground-glass (on CT). |
| Cavitation | Thick-walled cavity with air-fluid level. | Staph aureus (necrotizing), Klebsiella, Anaerobes (abscess), TB. | Central lucency (air). Surrounding consolidation. |
| Pleural Effusion | Blunting of costophrenic angle. Meniscus sign. | Parapneumonic (reactive) or Empyema (pus). | Lateral CXR more sensitive (blunts posterior sulcus). |
CXR Findings Suggesting Complications:
- Pleural effusion (>50% of hemithorax): Consider empyema (needs drainage).
- Cavitation: Necrotizing pneumonia, abscess (poor prognosis, prolonged antibiotics needed).
- Multilobar involvement: Severe disease, higher mortality.
- Pneumothorax: Rare (necrotizing pneumonia, mechanical ventilation).
Follow-Up CXR:
- 6 weeks post-treatment for all patients >50 years OR smokers OR persistent symptoms.
- Purpose: Screen for underlying lung cancer (post-obstructive pneumonia - tumor blocks bronchus → infection behind it).
- Expected: Slow resolution (may take 4-12 weeks to fully clear). Residual shadowing common in elderly.
CT Chest - Indications
When to do CT:
- CXR normal but high clinical suspicion (Immunocompromised, elderly - early pneumonia may not show on CXR).
- Failure to improve after 48-72h antibiotics (Empyema, abscess, underlying malignancy).
- Recurrent pneumonia in same location (Rule out bronchial obstruction - tumor, foreign body).
- Suspected complications: Empyema, abscess, bronchiectasis.
- Atypical presentations: Immunocompromised (PCP - ground-glass opacities; Aspergillus - halo sign).
CT Findings:
- Tree-in-bud: Bronchiolar inflammation (infection, aspiration, bronchiectasis).
- Ground-glass opacities: Atypicals, viruses, PCP, pulmonary edema.
- Cavitation, abscess: Better delineation than CXR.
- Empyema: Loculated pleural collection, pleural thickening, "split pleura sign" (enhanced visceral and parietal pleura with fluid between).
Blood Tests
Routine
- FBC:
- Leukocytosis (>11 x 10⁹/L): Bacterial infection. Neutrophilia. Left shift (immature neutrophils - bands).
- Leukopenia (less than 4 x 10⁹/L): Severe sepsis, overwhelming infection, immunosuppression. Poor prognostic sign.
- Lymphopenia: Viral, atypicals.
- Thrombocytopenia: Severe sepsis, DIC.
- U&Es:
- Urea >7 mmol/L: Dehydration, renal hypoperfusion (sepsis). Part of CURB-65.
- Creatinine: Acute kidney injury (AKI) if ↑ (pre-renal from sepsis/dehydration).
- Sodium: Hyponatremia (less than 135 mmol/L) suggests Legionella (SIADH).
- CRP (C-Reactive Protein):
- Elevated (>50-100 mg/L): Bacterial infection. Higher levels correlate with severity.
- Normal CRP: May be early infection or viral/atypical (though CRP can be high in Legionella).
- Trending CRP: Useful to monitor treatment response (should ↓ by 48-72h if improving).
- LFTs: Deranged (↑ALT, ↑AST, ↑ALP) suggests Legionella or sepsis.
- Lactate: >2 mmol/L suggests tissue hypoperfusion (sepsis, septic shock). >4 mmol/L = severe sepsis.
- Glucose: Hyperglycemia (stress response, steroids, undiagnosed diabetes).
Microbiology
Sputum Culture:
- Indication: All hospitalized patients (especially severe CAP).
- Timing: Ideally before antibiotics (yield drops after first dose).
- Specimen: Purulent sputum (not saliva). Deep cough, early morning sample.
- Interpretation:
- >25 PMNs and less than 10 squamous epithelial cells per low-power field = good quality sample.
- Growth of typical pathogen (Pneumococcus, H. influenzae, Staph) in heavy growth (>10⁵ CFU/mL).
- Limitations: Low yield (40-50% sensitivity). Contamination with oral flora. Cannot expectorate (elderly, dehydrated, dry cough).
Blood Cultures:
- Indication: All hospitalized patients with moderate-severe CAP (CURB ≥2), especially if sepsis (fever >38°C + hypotension/tachycardia/confusion).
- Technique: 2 sets (4 bottles total) from different sites before antibiotics.
- Yield: Positive in 10-20% (higher if bacteremia - Pneumococcus 25%).
- Clinical Impact: Identifies organism, guides de-escalation of antibiotics, detects bacteremia (worse prognosis).
Urinary Antigen Tests:
| Test | Organism | Sensitivity | Specificity | Notes |
|---|---|---|---|---|
| Pneumococcal Urinary Antigen | S. pneumoniae | 70-80% | >90% | Remains positive for weeks post-treatment (not useful for monitoring). More sensitive than sputum culture. |
| Legionella Urinary Antigen | Legionella pneumophila serogroup 1 | 70-90% | >95% | Only detects serogroup 1 (80% of cases). Negative test doesn't exclude Legionella. False negative in non-serogroup 1. |
- Advantages: Non-invasive, rapid (same day), remains positive even after antibiotics started.
- NICE NG138: Offer urinary antigens for Pneumococcus and Legionella in moderate-severe CAP (CURB ≥2).
Viral PCR (Nasopharyngeal Swab):
- Indication: Flu season (October-March), pandemic setting (COVID-19), immunocompromised.
- Tests: Influenza A/B, SARS-CoV-2, RSV, Adenovirus (multiplex PCR panel).
- Impact: If positive for flu → add Oseltamivir (if less than 48h symptoms). If COVID-19 → isolation, consider Dexamethasone (if hypoxic).
Arterial Blood Gas (ABG)
Indication: All patients with SpO₂ less than 94% or signs of respiratory distress.
Key Parameters:
- PaO₂ (Partial pressure of oxygen):
- Normal: 10-13 kPa (75-100 mmHg) on room air.
- Hypoxemia: less than 8 kPa (less than 60 mmHg). Severity correlates with extent of consolidation (V/Q mismatch).
- PaCO₂ (Carbon dioxide):
- Normal/Low (4-6 kPa): Type 1 Respiratory Failure (V/Q mismatch).
- High (>6 kPa): Type 2 Respiratory Failure (ventilatory failure). Consider COPD, exhaustion, neuromuscular weakness. May need NIV/intubation.
- pH: Acidosis (less than 7.35) suggests sepsis (lactic acidosis), respiratory failure (hypercapnia).
- Lactate: >2 mmol/L = sepsis. >4 mmol/L = septic shock.
- Base Excess: Negative BE = metabolic acidosis (lactic acidosis from sepsis).
A-a Gradient (Alveolar-arterial O₂ gradient):
- Calculates difference between alveolar PO₂ (calculated) and arterial PO₂ (measured).
- ↑A-a gradient: V/Q mismatch (pneumonia), shunt.
- Normal A-a gradient + hypoxemia: Hypoventilation (neuromuscular, drug overdose).
Additional Investigations (Severe/Complicated Cases)
Pleural Fluid Analysis (If Effusion Present)
Indications for Diagnostic Pleural Tap:
- Pleural effusion >10mm on lateral CXR or USS.
- All patients with pleural effusion + pneumonia (to differentiate parapneumonic from empyema).
Send Pleural Fluid For:
| Test | Interpretation |
|---|---|
| Appearance | Straw-colored (parapneumonic), Purulent/cloudy (empyema), Frank pus (empyema). |
| pH | less than 7.2 = Empyema (needs chest drain). 7.2-7.4 = Complicated parapneumonic (may need drain). >7.4 = Simple parapneumonic (antibiotics only). |
| Glucose | less than 2.2 mmol/L = Empyema. |
| LDH | >1000 IU/L = Empyema/complicated. |
| Protein | >30 g/L = Exudate (infection, malignancy). less than 30 g/L = Transudate (heart failure). |
| WCC | >50,000 (neutrophils) = Empyema. |
| Gram Stain / Culture | Identifies organism. Positive in 60% of empyema. |
Light's Criteria (Exudate vs Transudate): Exudate if ANY of:
- Pleural fluid protein / Serum protein >0.5.
- Pleural fluid LDH / Serum LDH >0.6.
- Pleural fluid LDH >2/3 upper limit normal serum LDH.
Bronchoscopy
Indications (Not routine):
- Non-resolving pneumonia (persistent fever, no radiological improvement after 7-10 days).
- Suspected obstruction (tumor, foreign body).
- Immunocompromised (to obtain BAL for PCP, fungi, TB, CMV).
- Recurrent pneumonia in same location.
Samples: Bronchoalveolar lavage (BAL), bronchial washings, transbronchial biopsy.
Management Algorithm (NICE NG138 / BTS Guidelines)
SUSPECTED PNEUMONIA
(Cough + Fever + Breathlessness)
↓
CONFIRM DIAGNOSIS
- Clinical features
- CXR (consolidation)
↓
CALCULATE CURB-65
(Confusion, Urea>7, RR≥30, BPless than 90/60, Age≥65)
↓
┌───────────┼───────────┐
SCORE 0-1 SCORE 2 SCORE 3-5
(MILD) (MODERATE) (SEVERE)
↓ ↓ ↓
HOME CARE HOSPITAL ICU/HDU REVIEW
Oral Abx ADMISSION URGENT
↓
ANTIBIOTIC CHOICE
(Based on severity + local guidelines)
↓
MILD (CURB 0-1):
- Amoxicillin 500mg TDS PO x 5 days
- (Penicillin allergy: Doxycycline 200mg loading,
then 100mg OD OR Clarithromycin 500mg BD)
↓
MODERATE (CURB 2):
- Amoxicillin 500mg-1g TDS PO/IV
+ Clarithromycin 500mg BD PO/IV x 5-7 days
- (Penicillin allergy: Levofloxacin 500mg OD)
↓
SEVERE (CURB 3-5):
- Co-amoxiclav 1.2g TDS IV
+ Clarithromycin 500mg BD IV x 7-10 days
- (Penicillin allergy: Levofloxacin 500mg BD IV
+ Clarithromycin 500mg BD IV)
- Consider adding Vancomycin/Linezolid if
suspected MRSA (IVDU, post-flu, necrotizing)
↓
SUPPORTIVE CARE
- Oxygen (Target SpO₂ 94-98%)
- IV Fluids (if septic, dehydrated)
- Analgesia (paracetamol, opiates if pleuritic pain)
- VTE Prophylaxis (LMWH if inpatient)
↓
REVIEW AT 48-72 HOURS
- Clinically improving? (Apyrexial, less breathless)
- CRP trending down?
- Switch IV → PO antibiotics (if tolerating oral)
- Discharge if stable + CURB ≤1
↓
FAILURE TO IMPROVE?
- Repeat CXR / CT Chest (Empyema? Abscess?)
- Blood cultures, sputum culture
- Consider resistant organisms, atypicals
- Consult Respiratory / Microbiology
↓
TREATMENT COMPLETION
- Total 5-7 days antibiotics (uncomplicated)
- Longer if complications (empyema, abscess: 2-6 weeks)
- Safety net advice (return if worsening)
- Follow-up CXR at 6 weeks (if >50 years or smoker)
1. Antibiotic Therapy
Empirical Antibiotic Choice (NICE NG138 / BTS Guidelines)
Principles:
- Start antibiotics within 4 hours of hospital arrival (Sepsis 6 bundle if septic).
- Empirical therapy (covers most likely pathogens before culture results).
- De-escalate based on culture results and clinical response (antibiotic stewardship).
- Duration: 5 days usually sufficient for uncomplicated CAP (NICE NG138). Longer if severe, slow response, or complications.
Mild CAP (CURB 0-1) - Outpatient:
| Regimen | Dose | Duration | Notes |
|---|---|---|---|
| Amoxicillin (1st line) | 500mg PO TDS | 5 days | Covers Pneumococcus, H. influenzae. Well-tolerated. |
| Doxycycline (Penicillin allergy) | 200mg PO loading, then 100mg OD | 5 days | Covers atypicals + typical. |
| Clarithromycin (Alternative) | 500mg PO BD | 5 days | Covers atypicals. Less GI upset than Erythromycin. |
- Do NOT routinely add Clarithromycin to Amoxicillin in mild CAP (NICE NG138). Reserve dual therapy for moderate-severe.
Moderate CAP (CURB 2) - Hospital Admission:
| Regimen | Dose | Duration | Notes |
|---|---|---|---|
| Amoxicillin + Clarithromycin (1st line) | Amox 500mg-1g TDS PO/IV + Clarithro 500mg BD PO/IV | 5-7 days | Covers typical (Pneumococcus, H. flu) + atypicals (Legionella, Mycoplasma). |
| Levofloxacin (Penicillin allergy) | 500mg PO/IV OD | 5-7 days | Broad-spectrum fluoroquinolone. Covers typical + atypicals. Avoid if C. diff risk. |
- Switch IV → PO when clinically improving (apyrexial for 24h, tolerating oral, stable observations).
Severe CAP (CURB 3-5) - ICU/HDU:
| Regimen | Dose | Duration | Notes |
|---|---|---|---|
| Co-amoxiclav + Clarithromycin (1st line) | Co-amox 1.2g TDS IV + Clarithro 500mg BD IV | 7-10 days | Broad-spectrum. Covers Pneumococcus (including intermediate resistance), H. flu, Staph (not MRSA), atypicals. |
| Levofloxacin + Clarithromycin (Penicillin allergy) | Levo 500mg BD IV + Clarithro 500mg BD IV | 7-10 days | Double coverage for atypicals in severe disease. |
| Add Vancomycin or Linezolid (if MRSA suspected) | Vancomycin 15-20mg/kg BD IV OR Linezolid 600mg BD IV | 7-14 days | Suspect MRSA if: IVDU, post-influenza, necrotizing pneumonia, known MRSA carrier. |
Pathogen-Specific Therapy (If Identified)
Streptococcus pneumoniae:
- Penicillin-sensitive: Benzylpenicillin 1.2g QDS IV OR Amoxicillin 1g TDS PO.
- Penicillin-resistant (rare in UK): Co-amoxiclav or Ceftriaxone.
Staphylococcus aureus:
- MSSA (Methicillin-sensitive): Flucloxacillin 2g QDS IV.
- MRSA (Methicillin-resistant): Vancomycin 15-20mg/kg BD IV (target trough 15-20 mg/L) OR Linezolid 600mg BD IV/PO.
Legionella pneumophila:
- Fluoroquinolone (1st line): Levofloxacin 500mg BD IV/PO x 7-10 days.
- Alternative: Azithromycin 500mg OD IV/PO x 5-10 days.
- Severe: Add Rifampicin 600mg BD PO (synergistic).
Mycoplasma pneumoniae:
- Macrolide (1st line): Clarithromycin 500mg BD PO x 7-10 days OR Azithromycin 500mg OD x 3 days.
- Alternative: Doxycycline 100mg BD PO x 7-10 days.
Influenza:
- Oseltamivir (Tamiflu): 75mg BD PO x 5 days if less than 48h from symptom onset OR severe disease (any time). Consider in all hospitalized flu patients.
2. Supportive Care
Oxygen Therapy
- Target SpO₂: 94-98% in non-COPD patients. 88-92% if COPD (avoid hypercapnia).
- Delivery:
- Nasal cannula: 1-4 L/min (24-40% FiO₂).
- Simple face mask: 5-10 L/min (40-60% FiO₂).
- Non-rebreather mask + reservoir: 15 L/min (60-90% FiO₂).
- High-flow nasal oxygen (HFNO): 30-60 L/min, warmed, humidified. For severe hypoxia.
- Monitor: SpO₂ continuously (if severe), ABG (if SpO₂ less than 94% or deteriorating).
Fluid Resuscitation (If Sepsis)
- Sepsis 6 Bundle (within 1 hour):
- Give high-flow oxygen (target SpO₂ 94-98%).
- Take blood cultures.
- Give IV antibiotics (broad-spectrum).
- Measure lactate and full blood count.
- Give IV fluid challenge (500mL crystalloid over 15 min if hypotensive or lactate >2 mmol/L).
- Measure urine output (catheterize if anuric).
- Fluid choice: 0.9% Saline or Hartmann's (crystalloid). Avoid starches (ARDS risk).
- Target: MAP ≥65 mmHg, Urine output >0.5 mL/kg/h, Lactate clearance.
- Caution: Avoid fluid overload in elderly/heart failure (pulmonary edema). Reassess frequently.
Analgesia
- Paracetamol: 1g QDS PO/IV (fever, mild-moderate pain).
- Opiates: Morphine 2.5-10mg IV PRN or Oxycodone 5-10mg PO PRN (severe pleuritic pain). Caution: respiratory depression.
- NSAIDs: Generally avoid (AKI risk in sepsis, GI bleeding).
VTE Prophylaxis
- All hospitalized patients should receive LMWH (enoxaparin 40mg SC OD or dalteparin 5000 units SC OD) unless contraindicated (active bleeding, platelets less than 50).
- Mechanical: TED stockings, intermittent pneumatic compression (if LMWH contraindicated).
Nutrition
- Maintain oral intake if possible. High-calorie, high-protein diet.
- NG feeding if unable to swallow safely (dysphagia, reduced GCS).
- IV fluids: Maintenance (25-30 mL/kg/day) if NBM.
3. Escalation of Care (Severe CAP / Deteriorating Patients)
Criteria for ICU/HDU Admission (CURB 3-5 OR)
- Respiratory Failure: SpO₂ less than 90% despite high-flow O₂. PaO₂ less than 8 kPa. RR >30.
- Septic Shock: Hypotension (SBP less than 90) requiring vasopressors (Noradrenaline).
- Multi-organ Failure: AKI (oliguria, Cr >300), confusion (encephalopathy), coagulopathy.
- Need for Invasive Ventilation or Non-Invasive Ventilation (NIV).
Non-Invasive Ventilation (NIV) - CPAP/BiPAP
- Indication: Type 1 Respiratory Failure (hypoxia) refractory to high-flow O₂. COPD with Type 2 Failure (hypercapnia).
- Contraindications: Vomiting, facial trauma, reduced GCS (less than 8), pneumothorax (untreated).
Invasive Mechanical Ventilation
- Indication: Severe hypoxia refractory to HFNO/NIV. Exhaustion. Airway protection (GCS less than 8).
- Complications: Ventilator-associated pneumonia (VAP), barotrauma, prolonged weaning.
Vasopressors (Septic Shock)
- Noradrenaline: 1st line. Target MAP ≥65 mmHg.
- Fluid Resuscitation first (30 mL/kg crystalloid bolus), then vasopressors if still hypotensive.
4. Monitoring and Review
Daily:
- Observations: Temp, HR, BP, RR, SpO₂. NEWS2 score (early warning score).
- Clinical: Cough improving? Sputum clearing? Breathlessness easing?
- Bloods: FBC (WCC trending down?), CRP (should ↓50% by Day 3-4), U&Es (AKI?).
48-72 Hour Review:
- Switch IV → PO antibiotics if:
- Apyrexial for 24h.
- Hemodynamically stable (BP, HR normal).
- Tolerating oral intake.
- Oxygen requirement stable/improving.
- Discharge planning if CURB ≤1 and stable.
Failure to Improve:
- Definition: Persistent fever (>48h), worsening breathlessness, rising CRP, new/worsening CXR changes.
- Actions:
- Repeat CXR or CT Chest (empyema, abscess, underlying malignancy).
- Repeat blood cultures, send sputum.
- Consider resistant organisms (MRSA, Pseudomonas), atypicals (Legionella - check urinary antigen).
- Broadening antibiotics (add Clarithromycin if not already on it, add antipseudomonal - Piperacillin-Tazobactam).
- Consult Respiratory / Microbiology.
Early Complications (During Acute Illness)
1. Respiratory Failure
Type 1 (Hypoxemic):
- Mechanism: V/Q mismatch (consolidated alveoli perfused but not ventilated).
- ABG: PaO₂ less than 8 kPa, PaCO₂ normal or low (hyperventilation).
- Management: Oxygen therapy (escalate to HFNO, NIV, intubation if refractory).
Type 2 (Hypercapnic):
- Mechanism: Exhaustion, COPD, neuromuscular weakness.
- ABG: PaO₂ less than 8 kPa, PaCO₂ >6 kPa.
- Management: NIV (BiPAP), consider intubation if failing.
2. Sepsis and Septic Shock
- Incidence: 20-30% of hospitalized CAP patients develop sepsis.
- Definition: Life-threatening organ dysfunction due to dysregulated host response to infection.
- Clinical: SIRS (fever >38°C or less than 36°C, HR >90, RR >20, WCC >12 or less than 4) + Source (pneumonia).
- Septic Shock: Sepsis + Hypotension (MAP less than 65) requiring vasopressors despite fluid resuscitation. Lactate >2 mmol/L.
- Mortality: 30-50% (septic shock).
- Management: Sepsis 6 bundle (within 1 hour), ICU, vasopressors (noradrenaline).
3. Parapneumonic Effusion
- Incidence: 40% of pneumonia patients develop pleural effusion.
- Mechanism: Inflammation → increased capillary permeability → fluid exudate into pleural space.
- Classification:
- Simple (Uncomplicated): Sterile, small (less than 10mm), pH >7.4. Resolves with antibiotics alone.
- Complicated: Larger, pH 7.2-7.4, glucose less than 2.2, LDH >1000. Risk of organization → empyema. May need chest drain.
- Investigation: Diagnostic pleural tap (all effusions >10mm). Send for pH, glucose, LDH, protein, Gram stain, culture.
- Management:
- Simple: Antibiotics only.
- Complicated or Empyema: Chest drain (pigtail catheter or large bore). Consider intrapleural fibrinolytics (tPA + DNase) if loculated. VATS if not resolving.
4. Empyema (Pus in Pleural Space)
- Incidence: 5-10% of hospitalized pneumonia.
- Definition: Frank pus in pleural space OR bacteria on Gram stain/culture OR pH less than 7.2.
- Organisms: Streptococcus (Pneumococcus, Milleri group), Staph aureus, Anaerobes (aspiration).
- Clinical: Persistent fever despite antibiotics, pleuritic pain, breathlessness.
- Investigation: USS chest (loculated collection). Pleural tap (purulent, pH less than 7.2, glucose less than 2.2, positive culture).
- Management:
- Chest drain (large bore 20-24Fr or small bore with fibrinolytics).
- Prolonged antibiotics (3-6 weeks total: 2 weeks IV, then switch to PO).
- Intrapleural fibrinolytics: tPA 10mg + DNase 5mg via chest drain BD x 3 days (MIST-2 trial). Breaks down loculations.
- VATS (Video-Assisted Thoracoscopic Surgery): If not draining, organize fibrin, lung entrapped. Decortication.
- Open thoracotomy: Last resort (chronic empyema, thick pleural peel).
5. Lung Abscess
- Incidence: 1-2% (higher with Staph, Klebsiella, aspiration).
- Mechanism: Necrotizing pneumonia → cavity formation → pus-filled cavity with air-fluid level.
- Risk Factors: Aspiration (alcoholics, poor dentition, neurological disease), anaerobes, Staph, Klebsiella, immunosuppression.
- Clinical: Persistent fever, copious foul-smelling sputum (anaerobes), hemoptysis, weight loss.
- CXR: Thick-walled cavity (>4mm) with air-fluid level. Usually in dependent zones (posterior segments).
- CT Chest: Confirms diagnosis, excludes mimics (empyema with bronchopleural fistula, cavitating tumor).
- Management:
- Prolonged antibiotics (4-6 weeks):
- Aspiration/Anaerobes: Co-amoxiclav 1.2g TDS IV → Amoxicillin 1g TDS PO + Metronidazole 400mg TDS PO.
- Staph/Klebsiella: As per sensitivities (Flucloxacillin, Meropenem).
- Postural drainage: Physiotherapy to drain pus.
- Percutaneous drainage: If large, not responding (CT/USS-guided pigtail catheter).
- Surgery (lobectomy): Rarely needed. If massive hemoptysis, failed medical therapy, or concern for malignancy.
- Prolonged antibiotics (4-6 weeks):
6. Atrial Fibrillation (AF)
- Incidence: 5-10% of hospitalized pneumonia (especially elderly).
- Mechanism: Hypoxia, sepsis, inflammation, electrolyte imbalance (hypokalemia, hypomagnesemia).
- Management:
- Treat underlying pneumonia (often reverts to sinus rhythm).
- Rate control: Bisoprolol 2.5-5mg OD PO or Digoxin 125-250mcg OD PO (if heart failure).
- Anticoagulation: Consider DOAC (Apixaban, Rivaroxaban) if CHA₂DS₂-VASc ≥2 and not contraindicated.
Late Complications (Post-Recovery)
7. Organizing Pneumonia (BOOP - Bronchiolitis Obliterans Organizing Pneumonia)
- Mechanism: Incomplete resolution → granulation tissue fills alveoli and bronchioles.
- Clinical: Persistent cough, breathlessness, malaise beyond 4-6 weeks.
- CXR: Persistent consolidation or migratory infiltrates.
- CT: Crazy-paving pattern, consolidation, ground-glass.
- Management: Steroids (Prednisolone 0.75mg/kg/day, taper over 6-12 months). Usually good response.
8. Bronchiectasis
- Mechanism: Necrotizing pneumonia (Staph, Klebsiella, severe Pneumococcus) → permanent bronchial dilation, fibrosis.
- Clinical: Chronic productive cough, recurrent infections, hemoptysis.
- CT Chest: Bronchial dilation (signet ring sign), bronchial wall thickening.
- Management: Airway clearance (physiotherapy), mucolytics, antibiotics for exacerbations, inhaled steroids.
9. Post-Pneumonia Fatigue Syndrome
- Incidence: 50-70% report fatigue lasting >6 weeks.
- Mechanism: Inflammatory cytokines, muscle deconditioning, psychological stress.
- Clinical: Profound fatigue, reduced exercise tolerance, low mood.
- Management: Reassurance (usually resolves over 3-6 months), graded exercise, nutrition.
Mortality
Overall:
- Community (Outpatient): less than 1% (CURB 0-1).
- Hospital (Inpatient): 5-10% (CURB 2).
- ICU (Severe): 15-40% (CURB 3-5).
Factors Associated with Higher Mortality:
- Age: >65 years. Incremental risk with each decade.
- Comorbidities: COPD, heart failure, CKD, diabetes, immunosuppression, malignancy.
- Severity: High CURB-65 score, multilobar involvement, cavitation, empyema.
- Organism: Staph aureus (30-40%), Legionella (10-20%), Gram-negatives (20-30%). Pneumococcus (5-10%).
- Septic shock: Requiring vasopressors (30-50% mortality).
- Delayed antibiotics: >4 hours from hospital arrival increases mortality.
30-Day Mortality by CURB-65:
- 0: less than 1%.
- 1: 3%.
- 2: 9%.
- 3: 15%.
- 4: 40%.
- 5: 57%.
Recovery Time
- Clinical Improvement: Fever resolves by Day 2-3. Cough improves by Day 7-10.
- Radiological Resolution: Lags behind clinical. CXR clears over 4-12 weeks.
- Pneumococcus: 4-6 weeks.
- Staph / Legionella: 8-12 weeks (or longer).
- Functional Recovery: Return to baseline activity by 4-6 weeks (younger patients). May take 3-6 months in elderly.
- Fatigue: Persistent in 50-70% for >6 weeks ("post-pneumonia fatigue syndrome").
Recurrence
- Incidence: 5-10% of patients have recurrent pneumonia (same location within 1 year).
- Risk Factors: COPD, smoking, asthma, bronchiectasis, immunosuppression, aspiration risk, structural lung disease.
- Investigation: If recurrent in same location → CT Chest (rule out bronchial obstruction - tumor, foreign body, stricture).
Prognostic Scores
PSI (Pneumonia Severity Index):
- US score, more complex than CURB-65 (20 variables).
- More accurate but less practical (not widely used in UK).
SMART-COP Score:
- Predicts need for ICU (IRVS - Intensive Respiratory or Vasopressor Support).
- 1 point each: Low BP (Sys less than 90), Multilobar CXR, Low Albumin less than 35, High RR (≥25 if age less than 50 or ≥30 if ≥50), Tachycardia ≥125, Confusion, Low Oxygen, Low pH less than 7.35.
Key Guidelines
| Guideline | Organisation | Key Recommendations |
|---|---|---|
| Pneumonia | NICE NG138 (2019) | 5 days antibiotics usually sufficient for uncomplicated CAP. |
| Antibiotics | BTS | Use CURB-65 to guide admission and antibiotic choice. |
Landmark Evidence
1. CURB-65 Validation
- British Thoracic Society study validated this simple score outperforming complex American scores (PSI) for practical triage.
What is Pneumonia?
It is a chest infection where the tiny air sacs (alveoli) at the end of your breathing tubes fill up with pus and fluid. This makes it hard to get oxygen into your blood.
Is it contagious?
You can catch the bacteria from coughs/sneezes, but usually people only get pneumonia if their immune system is a bit down (after a flu) or if they are elderly/smokers. It doesn't sweep through a house like flu does.
How is it treated?
Antibiotics. You often start to feel better within 48 hours, but the tiredness can last for 6 weeks.
Why do I need another X-ray?
Sometimes a lung cancer can block a tube and cause pneumonia behind the blockage. We repeat the X-ray in 6 weeks to check the infection has cleared and there is nothing "sinister" hiding underneath.
Primary Sources
- NICE. Pneumonia (community-acquired): antimicrobial prescribing (NG138). 2019.
- Lim WS, et al. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2009.
Common Exam Questions
- Diagnosis: "CURB-65 criteria?"
- Answer: Confusion, Urea>7, RR>=30, BPless than 90/60, Age>=65.
- Microbiology: "Urinary antigen?"
- Answer: Legionella and Pneumococcus.
- Complication: "Persistent fever + pleural fluid?"
- Answer: Empyema (Needs drainage).
- Pathogen: "Post-flu pneumonia?"
- Answer: Staph aureus.
Viva Points
- Bronchial Breathing: Pathophysiology. Sound is transmitted better through solid (consolidation) than air. So you hear the harsh tracheal sounds right out at the periphery.
- Atypicals: Why treat them? They don't respond to Penicillins. Always cover in severe disease.
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.